Common Drug Review recommendations: an evidence base for expectations?
about
Oncology drug health technology assessment recommendations: Canadian versus UK experiences.Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPDEvaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.Surrogate outcomes: experiences at the Common Drug Review.The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology.Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
P2860
Q33933850-DA4F041B-F39A-481A-9178-9D7EC3257C55Q35681671-A58B65EE-8552-499F-94CA-C9D3035F389AQ36404862-C3070237-3926-4673-8120-1465E891EBC9Q36565394-90C11F74-89BB-4FD9-93FC-4747D747909DQ36590680-0B7A1755-48AC-459F-B6C1-54C50F828143Q37400903-F108FC8B-AF4D-4EE6-B001-6B9F1BF99AAEQ38074371-9DF9D66F-570E-4317-AC08-786DA0A8369EQ43620093-AC06C2E9-A59A-4380-A00E-67724D52EE64Q47123934-CA754C47-7030-43A3-8710-9B2D27F89133Q47137018-6AC0D3ED-0AF2-44B7-ABA3-F5671799FDEAQ47169342-44C6FF54-F493-48C5-ACD6-30A2E11ABC5CQ47220948-1CE6CB36-34D3-4D36-BB4C-1DB4B910C7B0Q49574177-D986B936-ACA5-47F8-94AF-641452F8E2DBQ50111490-76CA12FE-9B52-4B14-ABFF-CDB3CE6EA2FE
P2860
Common Drug Review recommendations: an evidence base for expectations?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Common Drug Review recommendations: an evidence base for expectations?
@en
Common Drug Review recommendations: an evidence base for expectations?
@nl
type
label
Common Drug Review recommendations: an evidence base for expectations?
@en
Common Drug Review recommendations: an evidence base for expectations?
@nl
prefLabel
Common Drug Review recommendations: an evidence base for expectations?
@en
Common Drug Review recommendations: an evidence base for expectations?
@nl
P2093
P2860
P1433
P1476
Common Drug Review recommendations: an evidence base for expectations?
@en
P2093
Angela Rocchi
Elizabeth Miller
Ron Goeree
P2860
P304
P356
10.2165/11593030-000000000-00000
P577
2012-03-01T00:00:00Z
P6179
1043242300